Mike Toth Head and Neck Cancer Research Center

The Mike Toth Head and Neck Cancer Research Center is committed to creating better outcomes for head and neck cancer patients. Made possible by a gift from long-time friends of Mass. Eye and Ear, Michelle and Bob Atchinson, in honor of their friend, Mike Toth, our investigations primarily focus on the advancement of treatment for head and neck cancers, including cancer of the oral cavity, pharynx, larynx, salivary glands, and thyroid and parathyroid glands.

With a large patient population and a sizable tumor bank, both of which are critical for testing potential new therapies, we are uniquely positioned to make a real impact in advancing head and neck cancer research. By introducing a new hub for collaboration, this center aims to forge relationships in order to bring emerging cancer research strategies to head and neck cancer, which can ultimately expedite breakthroughs in treatment.

Some of our current ongoing projects include:

  • ECOG-Phase II radnomized trail of neo-adjuvant chemotherapy followed by surgery and post-operative radiation vesus surgery and post-operative radiation for organ preservation of T3 and Y4a nasal and paranasal sinus SCC
  • Assessment of quality of life and tongue ROM in oral cavity cancer patients six months after treatment
  • A prospective Phase I and Phase II neoadjuvant trial of Avelumab in patients with HPV negative head and neck SCC
  • Adenoid cystic carcinomas pathology/tissue banking
  • Near-infrared hybrid optical/x-ray CT for diagnosis and surveillance of superficial lymph nodes and neck cancer
  • Functional status assessment for complication prediction and disposition planning following major otolaryngology-head and neck surgery procedures